[Ferroprotein succinylate: treatment of iron deficiency in obstetrics and gynecology].
Aim of this multicentric clinical trial was to evaluate the efficacy and tolerability of a new iron compound: iron proteinsuccinylate. 3,200 patients affected with iron deficiency due to obstetric or gynecologic etiology were treated with iron proteinsuccinylate, at a daily dose of 80 mg Fe3+, for at least 30 days. Iron proteinsuccinylate induced a statistically significant improvement (p less than 0.01) in mean values of hemoglobin and serum iron. The compound also caused a disappearance or improvement of subjective symptomatology (asthenia, anorexia) and of clinical conditions deriving from iron deficiency state (polypnea, cutaneous and mucous pallor). The treatment was well tolerated and caused a few slight side effects (diarrhea, epigastralgia, nausea) in 2.4% of patients.
Sallusto
A
A
Ospedale di Cremona, Divisione di Ostetricia e Ginecologia.
Eandi
M
M
De Bartolo
G
G
Curiale
C
C
Massobrio
M
M
D000747:Anemia, Hypochromic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008667:Metalloproteins / Q000627:therapeutic use*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood* / Q000188:drug therapy; D013386:Succinates / Q000627:therapeutic use*
D008667:Metalloproteins; D013386:Succinates; C055066:iron protein succinylate
Il ferroproteinsuccinilato: terapia della carenza marziale in ostetricia e ginecologia.